Emil deGoma, M.D.

Emil deGoma, M.D., FACC, FAHA is Chief Medical Officer at Braveheart Bio, with extensive experience in medical research, clinical medicine, and drug development across prevalent and rare cardiovascular diseases.

Prior to his current role, Emil served as SVP of Medical Research at Tourmaline Bio, leading the pacibekitug program in cardio-immunology; SVP of Clinical Development at ChemoCentryx (Tavneos); and VP of Clinical Development at Akebia Therapeutics (Vafseo).

Emil received an A.B. in Biochemical Sciences from Harvard College and earned his M.D. from Harvard Medical School. He completed his internal medicine residency, chief residency, and cardiology fellowship at Stanford University, where he trained in the Center for Inherited Cardiovascular Disease, followed by a vascular medicine fellowship at the University of Pennsylvania.

‍